RaDes GmbH
About us
RaDes offers contract development of semi-solid and liquid formulations based on an excellent scientific understanding and deep know-how of the pharmaceutical industry.
Our Rational Design approach sets new standards for semi-solid product development, making it more efficient, faster and less costly. We are also able to systematically solve difficult formulation challenges and to develop innovative products.
With this, we turn ideas and molecules into pharmaceutical and skin care products that are technically sound, regulatory convincing, appealing to the patient and that maximize exclusivity/IP.
We offer solutions for the entire development spectrum from innovative concept design, through the regulated environment of confirmatory development, to the support in trouble shooting of existing products. In addition we develop topical generics from reverse engineering to equivalence testing, including microstructure/rheology and IVRT/PT. The combination of the ability to recognize recurring patterns, a scientifically systematic approach and the targeted use of modern analytical methods and statistical optimization enable us to rationally design formulations with regards to the performance of the product as well as its regulatory and economic aspects.
Together with our clients we develop individual solutions that are adapted to the specific challenge to achieve the best value for the resources used.
RaDes GmbH is fully independent and located in Hamburg, Germany, with 200 square meters lab space equipped with modern instruments for formulation development, performance testing and analytical characterization.
Keywords: topicals, dermatology, ophthalmology, formulation development, HPLC, UPLC, rheology, semi-solids, semisolid, excipient analytics, polysorbate, petrolatum, stability studies, performance testing, in vitro models, IVRT, IVPT, skin penetration, creams, gels, ointments, emulsions, foams, NCE, repurposing, reformulation, probiotics, live biotherapeutic products , OTC, generics, preclinical/tox batch manufacturing. skin, nasal, nail, ungual, eye, ophthalmology, buccal, mucosal, vaginal, rectal, dermatitis, psoriasis, inflammatory, irritation, infection, wound healing
Address
Schnackenburgallee 114
22525 Hamburg
Germany
E-mail: michael.herbig@rades-development.com
Phone: +49 40 57004180
Internet: rades-development.com/en/
Contact person:
Products & Services
Novel topical formulations of mometasone furoate
Novel, innovative formulation of mometasone furoate with the following benefits:
Innovative formulations (no other emulsion and foam on market). European patent granted (EP4108235 B1). US patent filed (US 2022/0409634). Unique features include > 60% water, no hexylene glycol (=propane diol), no paraffin
Clear patient benefits, e.g. for scalp psoriasis and treatment of hairy skin. Non-greasy formulations as preferred by many patients.
Robust, rational design: around 90% saturation of active => high thermodynamic driving force for skin penetration without risk of re-precipitation
Convenient sourcing of excipients and low cost of goods expected: well-established excipients only, > 60% water.
Straight-forward manufacturing process: standard emulsification process, standard equipment, large design space; successfully scaled up to 600 kg
Very good tolerability of vehicle expected: free from potentially problematic excipients such as paraffin, cetyl alcohol, parabens, alcohols. Low concentrations of emulsifiers
Range of three formulation types to build a diverse portfolio,
Technically closely related emulsion, cream and foam which provide many synergies:
foam = identical emulsion, only with propellant.
Cream = 99 % same as emulsion, only different thickener
Rationally designed, lean formulations which are well understood in their critical quality attributes
Backup formulations available and covered in patent (e.g. emulsion variant with higher penetration, aerosol foams with stabilizers for stronger foams with richer skin feel)